For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | - | 0* | - | - |
| Research and development | 13,397,977 | 10,402,327* | 8,970,010 | 6,996,660 |
| General and administrative | 6,599,759 | 4,934,491* | 3,708,959 | 2,735,401 |
| Total operating expenses | 19,997,736 | 15,336,818* | 12,678,969 | 9,732,061 |
| Loss from operations | -19,997,736 | -15,336,818* | -12,678,969 | -9,732,061 |
| Changes in fair value of warrant liabilities | 482,474 | 24,822,933* | -61,598,908 | 627,056 |
| Interest expense | 62,745 | 79,208.5* | 43,292 | 64,345 |
| Interest income | 1,047,197 | 428,839.5* | 655,233 | 13,562 |
| Other income | 626,873 | 1,541,517.5* | 765,881 | 295,630 |
| Warrant issuance cost | - | - | 4,852,292 | - |
| Warrant issuance expense | - | 1,213,073* | - | - |
| Total other income | 1,128,851 | -24,144,857.5* | 58,124,438 | -382,209 |
| Net gain | -18,868,885 | -39,481,675.5* | 45,445,469 | -10,114,270 |
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | - | 46,366* | - | - |
| Foreign currency translation gain (loss) | - | 34,114* | - | - |
| Total comprehensive income (loss) | - | -39,401,195.5 | - | - |
| Basic EPS | -0.35 | -1.037 | 0.5 | -1.09 |
| Diluted EPS | -0.35 | -0.642 | -0.21 | -1.09 |
| Basic Average Shares | 53,558,639 | 37,980,425 | 10,660,500 | 9,294,469 |
| Diluted Average Shares | 53,558,639 | 61,340,193* | 77,863,263 | 9,294,469 |
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)